Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention PEPFAR, the most common co-covered peer. Health Security Policy Academy appears in 1 tracked Biotech story from July 12, 2026.
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention PEPFAR, the most common co-covered peer. Health Security Policy Academy appears in 1 tracked Biotech story from July 12, 2026. The tracked stories average 4 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Health Security Policy Academy. Shared-story counts are live from our verified record — not editorial picks.
For biopharma manufacturers, the restructuring of PEPFAR and the September award expirations threaten high-volume procurement contracts and stable antiretroviral demand. The cliff could disrupt clinical trial infrastructure, inventory planning, and generic drug production that have relied on predictable US funding for over two decades.
Source: edition.cnn.com · cbs58.com
Health Security Policy Academy is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
